D. E. Shaw & Co., Inc.
- SEC CIK
- 0001009207
- Latest filing
- Aug 14, 2026
ARWR holding history
Arrowhead Pharmaceuticals, Inc. in every 13F filed by D. E. Shaw & Co., Inc., including the quarters it was sold out or no filing was made. Changes compare share counts with the previous calendar quarter.
ARWR overviewAll 13F holders of ARWRFull Q2 2026 holdings
- Shares (Q2 2026)
- 431,560
- Value
- $35.2M
- % of portfolio
- <0.1%
- Quarters held
- 12
- Since Q1 2021
| Quarter | Shares | Value | % of portfolio | Share change | Action | All holders |
|---|---|---|---|---|---|---|
| Q2 2026 | 431,560 | $35.2M | <0.1% | −752,278−63.5% | Reduced | Holders |
| Q1 2026 | 1,183,838 | $74.2M | 0.1% | +1,037,774+710.5% | Added | Holders |
| Q4 2025 | 146,064 | $9.70M | <0.1% | +125,763+619.5% | Added | Holders |
| Q3 2025 | 20,301 | $700.2K | <0.1% | +20,301 | New | Holders |
| Q1 2024 | 0 | $0 | 0.0% | −45,474−100.0% | Sold out | Holders |
| Q4 2023 | 45,474 | $1.39M | <0.1% | +45,474 | New | Holders |
| Q3 2023 | 0 | $0 | 0.0% | −31,390−100.0% | Sold out | Holders |
| Q2 2023 | 31,390 | $1.12M | <0.1% | +827+2.7% | Added | Holders |
| Q1 2023 | 30,563 | $776.3K | <0.1% | +30,563 | New | Holders |
| Q3 2022 | 0 | $0 | 0.0% | −8,189−100.0% | Sold out | Holders |
| Q2 2022 | 8,189 | $288.0K | <0.1% | +8,189 | New | Holders |
| Q1 2022 | 0 | $0 | 0.0% | −33,117−100.0% | Sold out | Holders |
| Q4 2021 | 33,117 | $2.20M | <0.1% | −8,789−21.0% | Reduced | Holders |
| Q3 2021 | 41,906 | $2.62M | <0.1% | −18,506−30.6% | Reduced | Holders |
| Q2 2021 | 60,412 | $5.00M | <0.1% | +16,227+36.7% | Added | Holders |
| Q1 2021 | 44,185 | $2.93M | <0.1% | – | – | Holders |
Livermore's 13F data starts with Q1 2021, so Q1 2021 has no change from the previous quarter.